AMARIN CORP PLC\UK Unrealized Gain (Loss) on Derivatives
AMARIN CORP PLC\UK (AMRN) reported Unrealized Gain (Loss) on Derivatives of $8.17 million for the 12-month period ending 2016-12-31, per its 10-K filed 2019-02-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2019-02-27
- AMARIN CORP PLC\UK unrealized gain (loss) on derivatives for the quarter ending 2016-12-31 was $0.00.
- AMARIN CORP PLC\UK unrealized gain (loss) on derivatives for the quarter ending 2016-09-30 was $3.61M.
- AMARIN CORP PLC\UK unrealized gain (loss) on derivatives for the quarter ending 2016-06-30 was $5.81M.
- AMARIN CORP PLC\UK unrealized gain (loss) on derivatives for the quarter ending 2016-03-31 was -$1.25M, a 369.40% decline year-over-year.
- AMARIN CORP PLC\UK unrealized gain (loss) on derivatives for fiscal 2016 was $8.17M.
- AMARIN CORP PLC\UK unrealized gain (loss) on derivatives for fiscal 2015 was -$1.11M, a 108.21% decline from fiscal 2014.
- AMARIN CORP PLC\UK unrealized gain (loss) on derivatives for fiscal 2014 was $13.47M, a 71.76% decline from fiscal 2013.
- AMARIN CORP PLC\UK unrealized gain (loss) on derivatives for fiscal 2013 was $47.71M.
| Period end | Unrealized Gain (Loss) on Derivatives 3 month | Unrealized Gain (Loss) on Derivatives 6 month | Unrealized Gain (Loss) on Derivatives 9 month | Unrealized Gain (Loss) on Derivatives 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $3.61M derived: sum of 2 quarters · filed 2019-02-27 | $9.42M derived: sum of 3 quarters · filed 2019-02-27 | $8.17M 10-K · filed 2019-02-27 |
| 2016-09-30 | $3.61M 10-Q · filed 2017-11-01 | $9.42M derived: sum of 2 quarters · filed 2017-11-01 | $8.17M 10-Q · filed 2017-11-01 | $7.43M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | $5.81M 10-Q · filed 2017-08-02 | $4.56M 10-Q · filed 2017-08-02 | $3.82M derived: sum of 3 quarters · filed 2018-02-27 | $3.59M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | -$1.25M 10-Q · filed 2017-05-03 | -$1.99M derived: sum of 2 quarters · filed 2018-02-27 | -$2.22M derived: sum of 3 quarters · filed 2018-02-27 | -$2.82M derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | -$740.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$970.00K derived: sum of 2 quarters · filed 2018-02-27 | -$1.57M derived: sum of 3 quarters · filed 2018-02-27 | -$1.11M 10-K · filed 2018-02-27 |
| 2015-09-30 | -$230.00K 10-Q · filed 2016-11-03 | -$830.00K derived: sum of 2 quarters · filed 2016-11-03 | -$366.00K 10-Q · filed 2016-11-03 | $1.24M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | -$600.00K 10-Q · filed 2016-08-04 | -$136.00K 10-Q · filed 2016-08-04 | $1.47M derived: sum of 3 quarters · filed 2017-03-01 | $5.93M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $464.00K 10-Q · filed 2016-05-05 | $2.07M derived: sum of 2 quarters · filed 2017-03-01 | $6.53M derived: sum of 3 quarters · filed 2017-03-01 | $9.54M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $6.07M derived: sum of 2 quarters · filed 2017-03-01 | $9.08M derived: sum of 3 quarters · filed 2017-03-01 | $13.47M 10-K · filed 2017-03-01 |
| 2014-09-30 | $4.47M 10-Q · filed 2015-11-04 | $7.48M derived: sum of 2 quarters · filed 2015-11-04 | $11.87M 10-Q · filed 2015-11-04 | $38.52M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-06-30 | $3.01M 10-Q · filed 2015-08-06 | $7.40M 10-Q · filed 2015-08-06 | $34.05M derived: sum of 3 quarters · filed 2016-02-25 | $32.65M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-03-31 | $4.39M 10-Q · filed 2015-05-08 | $31.04M derived: sum of 2 quarters · filed 2016-02-25 | $29.64M derived: sum of 3 quarters · filed 2016-02-25 | $48.48M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-12-31 | $26.65M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $25.25M derived: sum of 2 quarters · filed 2016-02-25 | $44.09M derived: sum of 3 quarters · filed 2016-02-25 | $47.71M 10-K · filed 2016-02-25 |
| 2013-09-30 | -$1.40M 10-Q · filed 2014-11-06 | $17.44M derived: sum of 2 quarters · filed 2014-11-06 | $21.06M 10-Q · filed 2014-11-06 | $54.40M derived: sum of 4 quarters · filed 2015-03-03 |
| 2013-06-30 | $18.84M 10-Q · filed 2014-08-07 | $22.46M 10-Q · filed 2014-08-07 | $55.80M derived: sum of 3 quarters · filed 2015-03-03 | $72.26M derived: sum of 4 quarters · filed 2015-03-03 |
| 2013-03-31 | $3.62M 10-Q · filed 2014-05-09 | $36.96M derived: sum of 2 quarters · filed 2015-03-03 | $53.42M derived: sum of 3 quarters · filed 2015-03-03 | $34.49M derived: sum of 4 quarters · filed 2015-03-03 |
| 2012-12-31 | $33.34M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-03 | $49.80M derived: sum of 2 quarters · filed 2015-03-03 | $30.87M derived: sum of 3 quarters · filed 2015-03-03 | -$35.34M 10-K · filed 2015-03-03 |
| 2012-09-30 | $16.45M 10-Q · filed 2013-11-07 | -$2.48M derived: sum of 2 quarters · filed 2013-11-07 | -$68.69M 10-Q · filed 2013-11-07 | -$37.95M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | -$18.93M 10-Q · filed 2013-08-08 | -$85.14M 10-Q · filed 2013-08-08 | -$54.41M derived: sum of 3 quarters · filed 2014-02-27 | $52.21M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | -$66.21M 10-Q · filed 2013-05-09 | -$35.48M derived: sum of 2 quarters · filed 2014-02-27 | $71.14M derived: sum of 3 quarters · filed 2014-02-27 | -$114.22M derived: sum of 4 quarters · filed 2014-02-27 |
| 2011-12-31 | $30.73M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $137.35M derived: sum of 2 quarters · filed 2014-02-27 | -$48.01M derived: sum of 3 quarters · filed 2014-02-27 | -$22.67M 10-K · filed 2014-02-27 |
| 2011-09-30 | $106.61M 10-Q · filed 2012-11-08 | -$78.75M derived: sum of 2 quarters · filed 2012-11-08 | -$53.40M 10-Q · filed 2012-11-08 | -$225.15M derived: sum of 4 quarters · filed 2013-02-28 |
| 2011-06-30 | -$185.36M 10-Q · filed 2012-08-08 | -$160.02M 10-Q · filed 2012-08-08 | -$331.77M derived: sum of 3 quarters · filed 2013-02-28 | -$333.14M derived: sum of 4 quarters · filed 2013-02-28 |
| 2011-03-31 | $25.34M 10-Q · filed 2012-05-08 | -$146.41M derived: sum of 2 quarters · filed 2013-02-28 | -$147.78M derived: sum of 3 quarters · filed 2013-02-28 | -$177.70M derived: sum of 4 quarters · filed 2013-02-28 |
| 2010-12-31 | -$171.75M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | -$173.12M derived: sum of 2 quarters · filed 2013-02-28 | -$203.04M derived: sum of 3 quarters · filed 2013-02-28 | -$205.15M 10-K · filed 2013-02-28 |
| 2010-09-30 | -$1.37M 10-Q · filed 2011-11-08 | -$31.29M derived: sum of 2 quarters · filed 2011-11-08 | -$33.40M 10-Q · filed 2011-11-08 | |
| 2010-06-30 | -$29.92M 10-Q · filed 2011-08-09 | -$32.03M 10-Q · filed 2011-08-09 | ||
| 2009-12-31 | $5.14M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |